Allard Jon, Lawthom Charlotte, Henley William, Mclean Brendan, Hudson Sharon, Tittensor Phil, Rajakulendran Sanjeev, Ellawela Shan, Pace Adrian, Shankar Rohit
Cornwall Intellectual Disability & Epilepsy Research (CIDER) Centre Cornwall Partnership NHS Foundation Trust, Bodmin, UK.
Swansea University, Swansea, UK.
Acta Neurol Scand. 2021 Mar;143(3):256-260. doi: 10.1111/ane.13368. Epub 2020 Nov 24.
A quarter of people with intellectual disability (ID) have epilepsy, compared to approximately one in a hundred across the general population. Evidence for the safe and effective prescribing of antiepileptic drugs (AEDs) for those with ID is, however, limited.
This study seeks to strengthen the research evidence around Eslicarbazepine Acetate (ESL), a new AED, by comparing response of individuals with ID to those from the general population who do not have ID.
A single data set was created through retrospective data collection from English and Welsh NHS Trusts. The UK-based Epilepsy Database Research Register (Ep-ID) data collection and analysis method were used.
Data were collected for 93 people (36 ID and 57 'no ID'). Seizure improvement of '>50%' was higher at 12 months for 'no ID' participants (56%), compared to ID participants (35%). Retention rates were slightly higher for those with ID (56% compared to 53%). Neither difference was significant.
Tolerance and Efficacy for ID and 'no ID' people in our data set were similar. Seizure improvement and retention rates were slightly lower than that found in other European data sets, but findings strengthen the evidence for the use of ESL in the ID population.
与普通人群中约百分之一的患病率相比，四分之一的智力残疾（ID）患者患有癫痫。然而，关于为ID患者安全有效地开具抗癫痫药物（AEDs）的证据有限。
本研究旨在通过比较ID患者与非ID普通人群的反应，加强围绕新型AED醋酸艾司利卡西平（ESL）的研究证据。
通过对英格兰和威尔士国民健康服务信托基金进行回顾性数据收集创建了一个单一数据集。使用了基于英国的癫痫数据库研究登记册（Ep-ID）的数据收集和分析方法。
收集了93人的数据（36名ID患者和57名“非ID”患者）。“非ID”参与者在12个月时癫痫发作改善“>50%”的比例更高（56%），而ID参与者为（35%）。ID患者的保留率略高（分别为56%和53%）。两者差异均不显著。
我们数据集中ID患者和“非ID”患者的耐受性和疗效相似。癫痫发作改善率和保留率略低于其他欧洲数据集，但研究结果加强了ESL在ID人群中使用的证据。
